Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10449732 | 0.84 | ALOX15 (0.44) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| SCHEMBL6591180 | 0.82 | PKM (0.47) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| Hydrochloric Acid SCHEMBL28894511 | 0.82 | ALOX15 (0.42) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| Hydrochloric Acid SCHEMBL23071292 | 0.80 | PKM (0.46) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| SCHEMBL28797858 | 0.80 | CYP4F2 (0.44) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| SCHEMBL6590939 | 0.80 | ALOX15 (0.41) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| Hydrochloric Acid SCHEMBL23071291 | 0.80 | PKM (0.46) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| SCHEMBL6589766 | 0.80 | CYP4F2 (0.44) | ALOX15CYP4F2CYP4A11CYP1A2ABCB11 | |
| SCHEMBL7198049 | 0.79 | CYP1A2 (0.47) | ALOX15CYP4F2CYP4A11CYP1A2PKM | |
| SCHEMBL27581225 | 0.79 | ALDH1A1 (0.47) | CYP1A2CYP3A4TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133067-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-6858383-B2 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6849650-B2 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030130188-A1 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THORSETT EUGENE D (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030027304-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
| CN-1253554-A | Heterocyclic compounds and their use for inhibiting 'beta'-amyloid peptide | ELAN MEDICINE CO (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0968198-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE | Elan Pharmaceuticals, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130188-A1 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | ALOX15 802/4885CYP4F2 4056/4885CYP4A11 2048/4885 |
| US-20030027304-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | SPHK1, SGPL1, SGMS1 | ALOX15 244/4885CYP4F2 3212/4885CYP4A11 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.